Funding
← Back to your selection

American Cancer Society BrightEdge

Activity from announced rounds

Activity in this selectionsempervirens-177768bc
Rounds participated in
1
Confirmed lead rounds
0
All roles disclosed
New companies
1
First participation on record · 0 follow-on
Funding in participating rounds
$33M
1 disclosed · full round size, not this investor’s share

By stage

Seed1

By primary sector

Biotech1

By country

United States1

Rounds

1 in this selection
Cloverleaf Bio

Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.

$33MSeed
Participant